Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545487 | 1.00 | KCNH2 (0.54) | KCNH2CYP19A1SLC2A1TGFBR1TGFBR2 | |
| SCHEMBL13349141 | 0.92 | KCNH2 (0.54) | KCNH2SLC2A1MTOR | |
| SCHEMBL3548451 | 0.89 | KCNH2 (0.55) | KCNH2SLC2A1MTOR | |
| SCHEMBL3548455 | 0.89 | KCNH2 (0.55) | KCNH2SLC2A1MTOR | |
| SCHEMBL3548508 | 0.88 | KCNH2 (0.42) | KCNH2CYP19A1 | |
| SCHEMBL3551596 | 0.87 | KCNH2 (0.60) | KCNH2SLC2A1MTOR | |
| SCHEMBL3552603 | 0.87 | KCNH2 (0.60) | KCNH2SLC2A1MTOR | |
| SCHEMBL3550302 | 0.87 | KCNH2 (0.60) | KCNH2SLC2A1MTOR | |
| SCHEMBL3545356 | 0.87 | KCNH2 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL3545352 | 0.87 | KCNH2 (0.53) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732461-B2 | (4S)-4-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-3-fluoro-4-hydroxy-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-7-one, used in the treatment of bacterial infections caused by a wide range of organisms including both gramnegative and grampositive bacteria | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | NRDC, NACA, ASNS | KCNH2 2161/4885CYP19A1 3208/4885SLC2A1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.